Program
Tamsulosin
Also written as “tamsulosin hydrochloride”, “Tamsulosin (0.4 mg/j)” and “tamsulosin”.
Its studies are mostly in Prostatic Hyperplasia · Lower Urinary Tract Symptoms · Erectile Dysfunction · Urologic Diseases · Urinary Bladder, Neurogenic, led by 15 companies.
Drug pageTamsulosin: every studyMany companies study it; this page follows only the 56 they lead. All 155 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheimits history only | 140 open or running | phase 4since Sep 18, 2014 | Jun 19, 2006 | none ahead |
| Astellas Pharmaits history only | 100 open or running | phase 4since Mar 17, 2016 | Jul 25, 2007 | none ahead |
| GlaxoSmithKline | 90 open or running | phase 4since Feb 10, 2011 | Aug 24, 2004 | none ahead |
| Hanmi Pharmaceuticalits history only | 50 open or running | phase 3since Feb 23, 2015 | Sep 4, 2014 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 30 open or running | phase 3since Sep 2, 2015 | Sep 15, 2014 | none ahead |
| Menarini Groupits history only | 33 open or running | phase 1since Jul 22, 2025 | Jul 22, 2025 | none ahead |
| GL Pharm Techits history only | 20 open or running | phase 3since Nov 11, 2014 | Feb 24, 2014 | none ahead |
| Jeil Pharmaceuticalits history only | 20 open or running | phase 3since Nov 21, 2016 | Jul 1, 2014 | none ahead |
| Teva Pharmaceutical Industriesits history only | 20 open or running | phase 1since Jun 22, 2010 | Jun 22, 2010 | none ahead |
| adiumits history only | 10 open or running | no phasesince Jul 7, 2026 | Jul 7, 2026 | none ahead |
| ascension-healthits history only | 10 open or running | phase 4since Nov 5, 2016 | Nov 5, 2016 | none ahead |
| Dexa Medica Groupits history only | 10 open or running | phase 1since Aug 14, 2024 | Aug 14, 2024 | none ahead |
| getz-pharmaits history only | 10 open or running | phase 4since Jul 7, 2023 | Jul 7, 2023 | none ahead |
| IlDong Pharmaceuticalits history only | 10 open or running | phase 3since Jul 22, 2016 | Jul 22, 2016 | none ahead |
| neotract-incits history only | 11 open or running | phase 4since Jul 9, 2021 | Jul 9, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of GlaxoSmithKline only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 24, 2004First study: phase 3 study in Prostatic HyperplasiaFirst studyNCT00090103 · 4,844 enrolled · United States, Argentina, Belgium and more
- Feb 10, 2011Phase 4 study in Prostatic HyperplasiaNCT01294592 · 742 enrolled · France, Germany, Greece and more
- Jun 28, 2012Phase 4 study in Prostatic HyperplasiaNCT01673490 · 59 enrolled · Vietnam
- Aug 2, 2012Phase 1 study in Prostatic HyperplasiaNCT01657851 · 35 enrolled · Russian Federation
- Jan 24, 2013Phase 4 study in Prostatic HyperplasiaNCT01777269 · 489 enrolled · Australia, France, Germany and more
- Oct 4, 2013Phase 1 study in Prostatic HyperplasiaNCT01957189 · 24 enrolled · China
- Jan 23, 2014Phase 3 study in Prostatic HyperplasiaNCT02058368 · 607 enrolled · China, Japan, Korea, Republic of and more
- Jan 30, 2014Phase 1 study in Urologic DiseasesNCT02052713 · 78 enrolled · United Kingdom
- Feb 6, 2014Phase 1 study in Urologic DiseasesNCT02058576 · 77 enrolled · United Kingdom
TargetBeta
“Adrenergic receptor alpha-1 antagonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Oxymetazolinerule | AbbVie | phase 4 | 20 |
| Phentolaminerule | opus-genetics-inc | phase 4 | 18 |
| Epinephrinerule | nasus-pharma | phase 4 | 17 |
| Midodrinerule | Takeda | phase 4 | 10 |
| Prazosinrule | Pfizer | phase 3 | 4 |
Studies
All 9 GlaxoSmithKline leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02058576Urologic Diseases · United Kingdom | 1 | Completed | Jan 2, 2015 | 77 |
| NCT02052713Urologic Diseases · United Kingdom | 1 | Completed | Dec 29, 2014 | 78 |
| NCT02058368Prostatic Hyperplasia · China, Japan, Korea, Republic of and more | 3 | Completed | Mar 3, 2017 | 607 |
| NCT01957189Prostatic Hyperplasia · China | 1 | Completed | Jan 22, 2014 | 24 |
| NCT01777269Prostatic Hyperplasia · Australia, France, Germany and more | 4 | Completed | Apr 5, 2016 | 489 |
| NCT01657851Prostatic Hyperplasia · Russian Federation | 1 | Completed | Dec 5, 2012 | 35 |
| NCT01673490Prostatic Hyperplasia · Vietnam | 4 | Terminated | Mar 20, 2015 | 59 |
| NCT01294592Prostatic Hyperplasia · France, Germany, Greece and more | 4 | Completed | Oct 17, 2013 | 742 |
| NCT00090103Prostatic Hyperplasia · United States, Argentina, Belgium and more | 3 | Completed | Apr 2009 | 4,844 |
How it is read
Names in the registry
- “Tamsulosin”, 12 entries
- “tamsulosin hydrochloride”, 6 entries
- “Tamsulosin (0.4 mg/j)”, 5 entries
- “tamsulosin”, 4 entries
- “HIP1402”, 3 entries
Conditions, from the studies’ own filings
- Prostatic Hyperplasia, 22 studies
- Lower Urinary Tract Symptoms, 6 studies
- Erectile Dysfunction, 3 studies
- Urologic Diseases, 2 studies
- Urinary Bladder, Neurogenic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.